ACTINOMYCES NEUII ENDOPHTHALMITIS AFTER INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR INJECTION.
OBJECTIVE
To describe a case of acute endophthalmitis caused by Actinomyces neuii after intravitreal anti-vascular endothelial growth factor injection.


METHODS
Observational case report, review of published literature.


RESULTS
A 67-year-old white man with wet age-related macular degeneration developed endophthalmitis secondary to A. neuii on the 10th day after intravitreal anti-vascular endothelial growth factor injection. Both anterior chamber and vitreous cultures were positive for A. neuii. He was treated successfully with intravitreal injection of vancomycin and ceftazidime.


CONCLUSIONS
This is the first published report of culture-positive endophthalmitis caused by A. neuii after intravitreal injection.
*Chicago Medical School, Rosalind Franklin University, North Chicago, Illinois; †UIC Department of Ophthalmology and Visual Sciences, Illinois Eye and Ear Infirmary, Chicago, Illinois; and ‡University Retina and Macula Associates, Oak Forest, Illinois.
Sakshi
S
Sahni
Randee Miller
RM
Watson
Veeral S
VS
Sheth
D000190:Actinomyces / Q000302:isolation & purification*; D000196:Actinomycosis / Q000175:diagnosis / Q000209:etiology* / Q000382:microbiology; D000368:Aged; D009877:Endophthalmitis / Q000175:diagnosis / Q000209:etiology* / Q000382:microbiology; D015818:Eye Infections, Bacterial / Q000175:diagnosis / Q000209:etiology* / Q000382:microbiology; D006801:Humans; D058449:Intravitreal Injections / Q000009:adverse effects; D008297:Male; D040262:Receptors, Vascular Endothelial Growth Factor / Q000008:administration & dosage / Q000819:agonists / Q000037:antagonists & inhibitors*; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage / Q000009:adverse effects*; D057135:Wet Macular Degeneration / Q000188:drug therapy
D011993:Recombinant Fusion Proteins; C533178:aflibercept; D040262:Receptors, Vascular Endothelial Growth Factor